# QUILT-2.008: Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma

> **NCT01029873** · PHASE1,PHASE2 · COMPLETED · sponsor: **Altor BioScience** · enrollment: 25 (actual)

## Conditions studied

- Metastatic Melanoma

## Interventions

- **DRUG:** Cisplatin
- **BIOLOGICAL:** ALT-801

## Key facts

- **NCT ID:** NCT01029873
- **Lead sponsor:** Altor BioScience
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-02
- **Primary completion:** 2011-11
- **Final completion:** 2013-09
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2016-10-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01029873

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01029873, "QUILT-2.008: Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT01029873. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*